1. Home
  2. ZLAB
  3. ZLAB News

Latest Zai Lab Limited (ZLAB) News on February 22, 2025

High Growth Tech Stocks To Watch In February 2025
ZLAB

Simply Wall St.

3 days ago

High Growth Tech Stocks To Watch In February 2025

With 73% ownership in Zai Lab Limited (NASDAQ:ZLAB), institutional investors have a lot riding on the business
ZLAB

Simply Wall St.

5 days ago

With 73% ownership in Zai Lab Limited (NASDAQ:ZLAB), institutional investors have a lot riding on the business

Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade
ZLAB

Zacks

25 days ago

Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
ZLAB

Business Wire

25 days ago

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

FDA grants ODD status to Zai Lab’s lung cancer treatment
ZLAB

Pharmaceutical Technology

a month ago

FDA grants ODD status to Zai Lab’s lung cancer treatment

ZLAB

MT Newswires

a month ago

Zai Lab Says FDA Grants Orphan Drug Designation for ZL-1310

Why Is Andreas Halvorsen Bullish On Zai Lab Limited (ZLAB) Now?
ZLAB

Insider Monkey

a month ago

Why Is Andreas Halvorsen Bullish On Zai Lab Limited (ZLAB) Now?

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
ZLAB

Business Wire

a month ago

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

High Growth Tech Stocks To Explore In January 2025
ZLAB

Simply Wall St.

a month ago

High Growth Tech Stocks To Explore In January 2025

Here’s Why Analysts Are Bullish on Zai Lab Limited (ZLAB)
ZLAB

Insider Monkey

a month ago

Here’s Why Analysts Are Bullish on Zai Lab Limited (ZLAB)

Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB)
ZLAB

Simply Wall St.

a month ago

Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB)

ZLAB

MT Newswires

a month ago

Sector Update: Health Care Stocks Softer Friday Afternoon

ZLAB

MT Newswires

a month ago

Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
ZLAB

Business Wire

a month ago

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Zai Labs announces positive results in China arm of Phase III cervical cancer trial
ZLAB

Clinical Trials Arena

a month ago

Zai Labs announces positive results in China arm of Phase III cervical cancer trial

ZLAB

MT Newswires

a month ago

Zai Lab Reports Improved Overall Survival in Phase 3 Trial of Tivdak in Cervical Cancer Patients

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
ZLAB

Business Wire

a month ago

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?
ZLAB

Zacks

a month ago

Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?

Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement
ZLAB

TipRanks

a month ago

Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement

ZLAB

MT Newswires

a month ago

Vertex, Zai Lab Partner Over Povetacicept Development in China, 4 Other Regions

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
ZLAB

Business Wire

a month ago

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
ZLAB

Business Wire

a month ago

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

ZLAB

MT Newswires

a month ago

Zai Lab Licenses MediLink Therapeutics' Antibody-Drug Conjugate Platform

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
ZLAB

Business Wire

a month ago

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock?
ZLAB

Zacks

2 months ago

Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock?

Zai Lab (NASDAQ:ZLAB) shareholders have endured a 59% loss from investing in the stock three years ago
ZLAB

Simply Wall St.

2 months ago

Zai Lab (NASDAQ:ZLAB) shareholders have endured a 59% loss from investing in the stock three years ago

Zai Lab Announces Participation in Investor Conference in January 2025
ZLAB

Business Wire

2 months ago

Zai Lab Announces Participation in Investor Conference in January 2025

Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint
ZLAB

TipRanks

3 months ago

Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint

ZLAB

MT Newswires

3 months ago

Update: NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
ZLAB

Benzinga

3 months ago

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients

ZLAB

MT Newswires

3 months ago

Zai Lab, NovoCure Say Pancreatic Cancer Trial Meets Primary Endpoint

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
ZLAB

Business Wire

3 months ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
ZLAB

Business Wire

3 months ago

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List

Exploring Three High Growth Tech Stocks in the United States
ZLAB

Simply Wall St.

3 months ago

Exploring Three High Growth Tech Stocks in the United States

Zai Lab and Pfizer to commercialise XACDURO in China
ZLAB

Pharmaceutical Technology

3 months ago

Zai Lab and Pfizer to commercialise XACDURO in China

ZLAB

MT Newswires

3 months ago

Zai Lab, Pfizer Collaborate for Marketing Antibacterial Drug in China

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
ZLAB

Business Wire

3 months ago

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
ZLAB

Business Wire

3 months ago

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

Analyst Estimates: Here's What Brokers Think Of Zai Lab Limited (NASDAQ:ZLAB) After Its Third-Quarter Report
ZLAB

Simply Wall St.

3 months ago

Analyst Estimates: Here's What Brokers Think Of Zai Lab Limited (NASDAQ:ZLAB) After Its Third-Quarter Report

ZLAB

MT Newswires

3 months ago

Zai Lab Prices $200 Million Public Offering

Zai Lab Announces Pricing of Public Offering of American Depositary Shares
ZLAB

Business Wire

3 months ago

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

Zai Lab Third Quarter 2024 Earnings: EPS Beats Expectations
ZLAB

Simply Wall St.

3 months ago

Zai Lab Third Quarter 2024 Earnings: EPS Beats Expectations

ZLAB

MT Newswires

3 months ago

Zai Lab Launches $200 Million ADS Offering; Stock Falls After-Hours

Zai Lab Announces Proposed Public Offering of American Depositary Shares
ZLAB

Business Wire

3 months ago

Zai Lab Announces Proposed Public Offering of American Depositary Shares

Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Path to Profitability
ZLAB

GuruFocus.com

3 months ago

Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Path to Profitability

Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics
ZLAB

Zacks

3 months ago

Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics

Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo
ZLAB

Pharmaceutical Technology

3 months ago

Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo

ZLAB

MT Newswires

3 months ago

Zai Lab's Q3 Loss Narrows, Revenue Rises

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
ZLAB

Business Wire

3 months ago

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

ZLAB

MT Newswires

3 months ago

Zai Lab, Argenx Receive Chinese Approval for Neuromuscular Drug Vyvgart Hytrulo

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
ZLAB

Business Wire

3 months ago

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia
ZLAB

Clinical Trials Arena

4 months ago

Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia

ZLAB

MT Newswires

4 months ago

Zai Lab's Schizophrenia Treatment KarXT Meets Primary Endpoint in Phase 3 Trial

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
ZLAB

Business Wire

4 months ago

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

High Growth Tech Stocks In The United States With Promising Potential
ZLAB

Simply Wall St.

4 months ago

High Growth Tech Stocks In The United States With Promising Potential

Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last?
ZLAB

Zacks

4 months ago

Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last?

Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results
ZLAB

Investor's Business Daily

4 months ago

Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results

ZLAB

MT Newswires

4 months ago

Zai Lab's Lung Cancer Treatment Candidate Shows 'Promising' Results in Trial; Shares Rise

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
ZLAB

Business Wire

4 months ago

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

Zai Lab Announces Participation in November and December Investor Conferences
ZLAB

Business Wire

4 months ago

Zai Lab Announces Participation in November and December Investor Conferences

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
ZLAB

Business Wire

4 months ago

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
ZLAB

Business Wire

4 months ago

Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024

Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
ZLAB

Business Wire

4 months ago

Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024

High Growth Tech Stocks To Watch In September 2024
ZLAB

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In September 2024

Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains?
ZLAB

Zacks

5 months ago

Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains?

Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
ZLAB

Business Wire

5 months ago

Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Zai Lab Limited (ZLAB): Top ADR Stock According to Hedge Funds
ZLAB

Insider Monkey

6 months ago

Zai Lab Limited (ZLAB): Top ADR Stock According to Hedge Funds

Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
ZLAB

Business Wire

6 months ago

Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024

High Growth Tech Stocks To Watch: Vertex And 2 Other Top Picks
ZLAB

Simply Wall St.

6 months ago

High Growth Tech Stocks To Watch: Vertex And 2 Other Top Picks

Zai Lab Announces Participation in September Investor Conferences
ZLAB

Business Wire

6 months ago

Zai Lab Announces Participation in September Investor Conferences

Zai Lab Limited (NASDAQ:ZLAB) institutional owners may be pleased with recent gains after 25% loss over the past year
ZLAB

Simply Wall St.

6 months ago

Zai Lab Limited (NASDAQ:ZLAB) institutional owners may be pleased with recent gains after 25% loss over the past year

ZLAB

MT Newswires

6 months ago

Sector Update: Health Care Stocks Lean Higher Pre-Bell Wednesday

ZLAB

MT Newswires

6 months ago

Zai Lab's Q2 Loss Narrows, Revenue Increases

Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
ZLAB

Business Wire

7 months ago

Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates

China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG
ZLAB

Pharmaceutical Technology

7 months ago

China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG

ZLAB

MT Newswires

7 months ago

Argenx, Zai Lab Get Chinese Regulator's Nod for Subcutaneous Add-on Injection Targeting Eneralized Myasthenia Gravis

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
ZLAB

Business Wire

7 months ago

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
ZLAB

Business Wire

7 months ago

Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy

ZLAB

MT Newswires

7 months ago

JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating

Best Momentum Stocks to Buy for July 10th
ZLAB

Zacks

7 months ago

Best Momentum Stocks to Buy for July 10th

Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
ZLAB

Business Wire

7 months ago

Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024

ZLAB

Argus Research

8 months ago

Daily – Vickers Top Buyers & Sellers for 07/01/2024

ZLAB

Argus Research

8 months ago

Daily – Vickers Top Buyers & Sellers for 06/28/2024

Insider Selling: Chairperson & CEO Ying Du Sells Shares of Zai Lab Ltd (ZLAB)
ZLAB

GuruFocus.com

8 months ago

Insider Selling: Chairperson & CEO Ying Du Sells Shares of Zai Lab Ltd (ZLAB)

ZLAB

MT Newswires

8 months ago

Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing

Increases to CEO Compensation Might Be Put On Hold For Now at Zai Lab Limited (NASDAQ:ZLAB)
ZLAB

Simply Wall St.

8 months ago

Increases to CEO Compensation Might Be Put On Hold For Now at Zai Lab Limited (NASDAQ:ZLAB)

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
ZLAB

Business Wire

8 months ago

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

Zai Lab doses first subject in Phase II plaque psoriasis treatment trial
ZLAB

Clinical Trials Arena

9 months ago

Zai Lab doses first subject in Phase II plaque psoriasis treatment trial

ZLAB

MT Newswires

9 months ago

Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
ZLAB

Business Wire

9 months ago

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

China’s NMPA approves Zai Lab’s XACDURO NDA for pneumonia
ZLAB

Pharmaceutical Technology

9 months ago

China’s NMPA approves Zai Lab’s XACDURO NDA for pneumonia

ZLAB

MT Newswires

9 months ago

Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
ZLAB

Business Wire

9 months ago

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

Insider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares
ZLAB

GuruFocus.com

9 months ago

Insider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares

Zai Lab Announces Participation in May and June Investor Conferences
ZLAB

Business Wire

9 months ago

Zai Lab Announces Participation in May and June Investor Conferences

ZLAB

MT Newswires

9 months ago

Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
ZLAB

Business Wire

9 months ago

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
ZLAB

Pharmaceutical Technology

9 months ago

BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC

ZLAB

MT Newswires

9 months ago

Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro

Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
ZLAB

Business Wire

9 months ago

Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA

Share on Social Networks: